RyR1 Structural Alterations Explain Statin-Associated Muscle Dysfunction
December 16, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Quadramet
Synonyms :
samarium sm 153 lexidronam
Class :
Radiopharmaceuticals
Brand Name :
Quadramet
Synonyms :
samarium sm 153 lexidronam
Class :
Radiopharmaceuticals
Dosage Forms & Strengths
Solution (Injectable)
1,850 MBq/ml
Administer 1 mCi/kg intravenously
Using a safe indwelling catheter, administer for 1 minute, then flush with saline solution
The patient must consume 500 milliliters of liquid and urinate frequently to decrease the amount of radiation exposure to the bladder
Safety and efficacy not determined in less than sixteen years old
Refer to adult dosing
Actions and Spectrum
samarium sm 153 lexidronam works by means of its radioactive characteristics. A radioisotope called samarium 153 generates high-energy beta particles that can enter and irradiate bone tissue. When samarium sm 153 lexidronam undergoes beta decay, beta particles with a maximum energy of about 810 keV are released.
Frequency defined
>10%
Leukopenia (59.3%)
Nausea/vomiting (32.7%)
Anemia (40.7%)
Thrombocytopenia (69.3%)
Frequency not defined
Ecchymosis
Pain flare
Myasthenia
Pathologic
Lymphadenopathy
Rash
Chest pain
Infections
Oral candidiasis
Abdominal pain
Epistaxis
HTN
Pneumonia
Hypotension
Diarrhea
Coagulation
Bronchitis
Spinal cord compression
CVA
Hematuria
Purpura
Paresthesia
Arrhythmias
Dizziness
Fever
Black Box Warning
None
Contraindication/Caution:
Contraindication:
Caution:
Pregnancy warnings:
Pregnancy category: D
Lactation: Discontinue the drug while lactation
Pregnancy Categories:
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category.
Pharmacology
EDTMP (ethylene diamine tetramethylene phosphonic acid) binds to samarium sm 153 lexidronam and functions as a chelator. The radioactive samarium can more easily reach the bone tissue because of their combination.
Bone metastases are one example of an area where EDTMP has a preference. The samarium-153-EDTMP complex preferentially accumulates in specific regions following intravenous injection, enabling targeted delivery of the radiation.
Pharmacodynamics
A targeted radiotherapy agent is samarium sm 153 lexidronam. To treat malignant bone lesions, it administers targeted radiation that has therapeutic benefits only on the bone tissue.
When samarium sm 153 lexidronam is given intravenously, the medication builds up in places with higher bone turnover, like bone metastases. In the malignant bone lesions, the released beta particles deposit their energy locally, causing a localized radiation exposure.
Pharmacokinetics
Absorption
samarium sm 153 lexidronam is injected straight into the bloodstream, this method of administration guarantees a quick and total bioavailability of the medication.
Distribution
samarium sm 153 lexidronam mostly affects bone tissue in distribution. The medication is particularly effective against bone metastases and other regions with high bone turnover. It attaches to hydroxyapatite crystals found in bone, enabling the radioactive samarium sm 153 to be delivered precisely to the bone lesions.
Metabolism
samarium sm 153 lexidronam is not significantly metabolized in the body. The drug is mainly excreted unchanged.
Elimination and excretion
samarium sm 153 lexidronam is primarily eliminated through the urine system. Renal excretion is the route via which the medication leaves the body. It is significant to remember that samarium sm 153 lexidronam undergoes radioactive decay over time, as is the case with other radioactive isotopes.
Administration
samarium sm 153 lexidronam is given intravenously with a slow injection or infusion.
A typical saline flush can be used alone or in combination with the medication.
Patient information leaflet
Generic Name: samarium sm 153 lexidronam
Why do we use samarium sm 153 lexidronam?
Nuclear medicine treats bone metastases by using samarium sm 153 lexidronam.
For patients with painful bone metastases, samarium sm 153 lexidronam is frequently used as palliative care.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
